PODD Stock Overview
Develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PODD from our risk checks.
Insulet Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$253.99 |
| 52 Week High | US$289.46 |
| 52 Week Low | US$160.19 |
| Beta | 1.3 |
| 1 Month Change | -0.57% |
| 3 Month Change | -4.89% |
| 1 Year Change | 46.02% |
| 3 Year Change | -1.17% |
| 5 Year Change | 24.52% |
| Change since IPO | 1,491.42% |
Recent News & Updates
Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet?
Apr 07
Insulet Leans Bullish (Technical Analysis)
Mar 18Recent updates
Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet?
Apr 07Insulet Leans Bullish (Technical Analysis)
Mar 18Calculating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Mar 05Insulet (NASDAQ:PODD) Is Experiencing Growth In Returns On Capital
Feb 18Earnings Not Telling The Story For Insulet Corporation (NASDAQ:PODD)
Jan 25What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?
Jan 13Here's Why Insulet (NASDAQ:PODD) Can Manage Its Debt Responsibly
Dec 18Here's Why Insulet (NASDAQ:PODD) Has Caught The Eye Of Investors
Dec 04Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Nov 20Does This Valuation Of Insulet Corporation (NASDAQ:PODD) Imply Investors Are Overpaying?
Nov 20Returns At Insulet (NASDAQ:PODD) Are On The Way Up
Nov 08Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues
Oct 15Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?
Oct 03Is Insulet (NASDAQ:PODD) A Risky Investment?
Sep 09Insulet: Turning More Constructive, Valuations Still Stretched
Sep 05Here's Why We Think Insulet (NASDAQ:PODD) Is Well Worth Watching
Aug 28
Omnipod 5'S Global Expansion And New Integrations Promise Growth Amid Market And Manufacturing Risks
Aug 22 Expansion into new international markets and integration with leading diabetes sensors position Insulet for increased global penetration and competitive advantage.Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings
Aug 16A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Jul 15Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
Jun 11We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)
May 26At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?
May 12Is Insulet (NASDAQ:PODD) A Risky Investment?
Apr 29Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors
Apr 14Insulet: Insulating Patients, Investors Still Have To Wait
Mar 28Insulet: An Interesting, Yet Expensive, Story
Jan 10Shareholder Returns
| PODD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.9% | 1.9% | 5.8% |
| 1Y | 46.0% | 1.7% | 4.8% |
Return vs Industry: PODD exceeded the US Medical Equipment industry which returned 1% over the past year.
Return vs Market: PODD exceeded the US Market which returned 3.6% over the past year.
Price Volatility
| PODD volatility | |
|---|---|
| PODD Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: PODD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PODD's weekly volatility (6%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 3,900 | Jim Hollingshead | www.insulet.com |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
Insulet Corporation Fundamentals Summary
| PODD fundamental statistics | |
|---|---|
| Market cap | US$17.84b |
| Earnings (TTM) | US$418.30m |
| Revenue (TTM) | US$2.07b |
42.6x
P/E Ratio8.6x
P/S RatioIs PODD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PODD income statement (TTM) | |
|---|---|
| Revenue | US$2.07b |
| Cost of Revenue | US$625.90m |
| Gross Profit | US$1.45b |
| Other Expenses | US$1.03b |
| Earnings | US$418.30m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | 5.96 |
| Gross Margin | 69.79% |
| Net Profit Margin | 20.19% |
| Debt/Equity Ratio | 114.9% |
How did PODD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 12:06 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Insulet Corporation is covered by 57 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anand Vankawala | Avondale Partners |
| Jeffrey Johnson | Baird |
| null null | Baird |